Kura Oncology, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $KURA in the last 7 days.
Insider trading activity for August 25, 2026, included purchases by executives at TTM Technologies (TTMI), Alpha Metallurgical (AMR), Kura Oncology (KURA), TEAM INC (TISI), and Dorchester Minerals (DMLP). Notable sales occurred at Corpay (CPAY), Aveanna Healthcare (AVAH), Micron Technology (MU), and NLIGHT (LASR). InvestingPro analysis provided fair value assessments for these companies.
Tenax Therapeutics (TENX) rose 27.8% premarket despite a Phase 3 trial setback, planning to discuss revised development plans with the FDA. TherapeuticsMD (TXMD) reported Q2 revenue decline but expects a milestone payment. Kura Oncology (KURA) gained 10.38% on strong Komzifti adoption. Anavex Life Sciences (AVXL) returned to profit in Q3 2026, advancing blarcamesine. Immatics (IMTX) rose 6.78% after a $150M offering. RenovoRx (RNXT) gained 16.40% on positive pancreatic cancer data.
Dick's Sporting Goods (DKS) fell 27% after reporting $5.59B in sales, missing estimates. Dynatrace (DT) rose 3% on a Morgan Stanley upgrade. Shift4 Payments (FOUR) gained 4% after a Wells Fargo upgrade. Moderna (MRNA) climbed 13% following a Wolfe Research upgrade. Marvell (MRVL) jumped 5% on higher price targets. AMD (AMD) rose 5% after a Raymond James upgrade. Kura Oncology (KURA) gained 10% after CEO bought shares. Navitas Semiconductor (NVTS) rose 5% on a $232.8M deal with Claros.
Recent KURA coverage spans financial news, market movers and insider activity.
In the last 30 days, KURA insiders filed 4 SEC Form 4 transactions — 2 purchases ($2.4M) and 2 sales ($449K). The most active reporter was WILSON TROY EDWARD, President and CEO, with 2 filings. 50% of those filings were made under pre-arranged Rule 10b5-1 plans.
Significant insider buying may boost sentiment.
Strong commercial traction supports price appreciation.
Insider buying indicates confidence.
Pre‑market surge points to positive short‑term sentiment.
Insider purchase signals confidence and may drive short‑term buying pressure.
alphai scores every news story that mentions KURA with an AI model for sentiment and relevance, and aggregates insider trades from Kura Oncology, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Insider trading activity for August 25, 2026, included purchases by executives at TTM Technologies (TTMI), Alpha Metallurgical (AMR), Kura Oncology (KURA), TEAM INC (TISI), and Dorchester Minerals (DMLP). Notable sales occurred at Corpay (CPAY), Aveanna Healthcare (AVAH), Micron Technology (MU), and NLIGHT (LASR). InvestingPro analysis provided fair value assessments for these companies.
3 min readTenax Therapeutics (TENX) rose 27.8% premarket despite a Phase 3 trial setback, planning to discuss revised development plans with the FDA. TherapeuticsMD (TXMD) reported Q2 revenue decline but expects a milestone payment. Kura Oncology (KURA) gained 10.38% on strong Komzifti adoption. Anavex Life Sciences (AVXL) returned to profit in Q3 2026, advancing blarcamesine. Immatics (IMTX) rose 6.78% after a $150M offering. RenovoRx (RNXT) gained 16.40% on positive pancreatic cancer data.
3 min readDick's Sporting Goods (DKS) fell 27% after reporting $5.59B in sales, missing estimates. Dynatrace (DT) rose 3% on a Morgan Stanley upgrade. Shift4 Payments (FOUR) gained 4% after a Wells Fargo upgrade. Moderna (MRNA) climbed 13% following a Wolfe Research upgrade. Marvell (MRVL) jumped 5% on higher price targets. AMD (AMD) rose 5% after a Raymond James upgrade. Kura Oncology (KURA) gained 10% after CEO bought shares. Navitas Semiconductor (NVTS) rose 5% on a $232.8M deal with Claros.
2 min readSeveral biotech stocks are trading higher in premarket, including Autonomix Medical (AMIX) up 29% at $6.92, Picard Medical (PMI) up 12% at $5.85, and others. The gains indicate early momentum and potential volatility for the trading day, according to the market activity.
1 min readKura Oncology's stock rose 11.6% in pre-market trading after CEO Troy Wilson bought 100,000 shares for $1.24 million, his second large purchase in a week. Analysts Citigroup and Jefferies reaffirmed positive ratings, citing strong commercial momentum for KOMZIFTI and Q2 earnings beat. The stock surpassed its 52-week high of $12.90.
2 min readKura Oncology (KURA) shares rose 11% premarket after CEO Troy Wilson bought $1.24M in stock, acquiring 100,000 shares at $12.39 average price. Wilson's total holdings now exceed 1.2M shares. Insider purchases may signal confidence in the company's prospects.
2 min readDick's Sporting Goods (DKS) shares fell 12% after reporting $5.59B revenue, below estimates. AMD (AMD) rose 2% following an upgrade to strong buy with a $641 target. Kura Oncology (KURA) climbed 11% after CEO's share purchase. Navitas Semiconductor (NVTS) jumped 5% on a $232.8M deal. United Airlines (UAL) gained 2.9% on new flight routes.
2 min readWILSON TROY EDWARD (President and CEO) purchased 100,000 indirectly-held shares of Kura Oncology, Inc. (KURA) at $12.39 ($1.24M total) on 2026-08-24.
1 min readKura Oncology (KURA) reported Q2 2026 earnings, with KOMZIFTI net product revenue up 57% QoQ to $9.1M. New patient starts increased 35% to 115, capturing majority market share in a specific leukemia segment. Total prescriptions rose 59% to 250. Cash decreased to $519M from $667.2M. Collaboration revenue guidance set at $45M-$55M for 2026. Net loss was $68.3M, up from $66.1M YoY. Clinical data showed strong results for ziftomenib and darlifarnib. Management expects pivotal trial results in 2028.
3 min readKura Oncology (NASDAQ:KURA) shares rose 5.4% in after-hours after CEO and President Troy Edward Wilson bought 100,000 shares on Aug. 17, 2026 at a weighted average $11.12 per share, per an SEC Form 4. Trades ranged from $10.87 to $11.31, totaling about $1.1 million.
2 min read
